FDA’s New RDEP: Not Just Clinical Data Matters
By Dr. Nathalie Machluf | October 2025
FDA’s New RDEP: Not Just Clinical Data Matters
By Dr. Nathalie Machluf | October 2025
FDA’s New RDEP: Not Just Clinical Data Matters
By Dr. Nathalie Machluf | October 2025
FDA Pre-IND Meeting: Not Just a Checkbox — A Strategic Tool to Reduce Time to Market
By Dr. Nathalie Machluf | March 2026
Early drug development is a critical phase in which key scientific and regulatory decisions can significantly influence the overall development program. Among the early regulatory interactions available to sponsors, the pre-IND meeting with the U.S. Food and Drug Administration (FDA) represents a particularly important strategic regulatory milestone.
3 Strategic Objectives
This meeting should not be viewed as a procedural formality. When approached strategically, the pre-IND meeting should aim to achieve three key outcomes:
-
Confirm development readiness
Ensure that integrated nonclinical, translational, and CMC programs have generated (or will generate through planned studies) a sufficiently robust package to support first-in-human clinical evaluation.
-
Evaluate the Phase I study design
Discuss the starting dose, escalation strategy, and safety mitigation measures within the context of the overall clinical development plan.
-
Clarify the regulatory pathway
Obtain feedback from the FDA on development strategy, regulatory expectations, and potential pathways that could facilitate development.
When properly prepared and strategically framed, the pre-IND meeting can provide substantial value to sponsors by clarifying regulatory expectations and strengthening the overall development strategy. In particular, a well-prepared pre-IND meeting enables sponsors to:
-
Validate the scientific rationale — Confirm that clinical development is supported by robust scientific evidence.
-
Ensure decision-enabling studies — Help planned studies generate meaningful data.
-
Identify potential vulnerabilities early — Detect gaps or weaknesses before they affect development timelines.
-
Reduce clinical hold probability — Proactively resolve regulatory questions and gaps to prevent holds during IND review.
-
Obtain clear and actionable FDA feedback — Confirm alignment on clinical and regulatory expectations for the intended indication in the target population.
As a result, the likelihood of a successful IND review outcome is increased, reducing the risk of unnecessary development delays and supporting an optimal program trajectory.
5 Key Benefits for Sponsors
4 Common Risk Areas
While preparing for a pre-IND meeting, sponsors should also be aware of common issues frequently raised during these interactions. Typical concerns include:
-
CMC uncertainties — Process reproducibility, product comparability, or analytical testing issues
-
Insufficient nonclinical support — Data gaps affecting the safety rationale for first-in-human exposure.
-
Weak starting dose justification — Inadequate rationale for dose selection or escalation scheme.
-
Clinical trial design concerns — Study population, endpoints, safety monitoring, or stopping rules.
Paying close attention to these aspects when planning and preparing for a pre-IND meeting ensures productive discussions and fosters a collaborative relationship with the regulator, based on scientific rigor and mutual trust.
CONCLUSION
The pre-IND meeting is the first major checkpoint for regulatory and scientific alignment with the FDA, laying the foundation for a successful short- and long-term development strategy and supporting efficient program execution to achieve timely market access.